Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Difelikefalin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 known ✓ | P41145 | 20/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Difelikefalin SCHEMBL10316464 | 1.00 | OPRK1 (1.00) | OPRK1OPRM1 | |
| Difelikefalin SCHEMBL18807719 | 1.00 | OPRK1 (1.00) | OPRK1OPRM1 | |
| Difelikefalin SCHEMBL18807843 | 1.00 | OPRK1 (1.00) | OPRK1OPRM1 | |
| Difelikefalin SCHEMBL20669281 | 1.00 | OPRK1 (1.00) | OPRK1OPRM1 | |
| Difelikefalin SCHEMBL18807733 | 1.00 | OPRK1 (1.00) | OPRK1OPRM1 | |
| Difelikefalin SCHEMBL25386632 | 1.00 | OPRK1 (1.00) | OPRK1OPRM1 | |
| Difelikefalin SCHEMBL18807720 | 1.00 | OPRK1 (1.00) | OPRK1OPRM1 | |
| SCHEMBL21286619 | 0.99 | OPRK1 (0.98) | OPRK1OPRM1 | |
| Difelikefalin SCHEMBL29993987 | 0.99 | OPRK1 (0.98) | OPRK1OPRM1 | |
| SCHEMBL23841287 | 0.99 | OPRK1 (0.98) | OPRK1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10035767-B2 | Method for producing synthetic pentapeptide | MARUISHI PHARMACEUTICAL CO., LTD. (JP) | 2018-07-31 | — | — | US | disclosed |
| US-20170183307-A1 | METHOD FOR PRODUCING SYNTHETIC PENTAPEPTIDE | MARUISHI PHARMACEUTICAL CO., LTD. (JP) | 2017-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035767-B2 | Method for producing synthetic pentapeptide | MRPL21, NGLY1, SPPL2A | OPRK1 3148/4885OPRM1 3461/4885 |
| US-20170183307-A1 | METHOD FOR PRODUCING SYNTHETIC PENTAPEPTIDE | MRPL21, NGLY1, SPPL2A | OPRK1 3148/4885OPRM1 3461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.